A carregar...
How I manage ibrutinib-refractory chronic lymphocytic leukemia
The introduction of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib has dramatically changed the management of chronic lymphocytic leukemia (CLL). Although responses have been durable in the majority of patients, relapses do occur, especially in the high-risk patient population. Most relapses o...
Na minha lista:
| Publicado no: | Blood |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Hematology
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5345730/ https://ncbi.nlm.nih.gov/pubmed/28096090 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-09-693598 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|